Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb657 in Healthy Participants and Autoimmune Diseases
NCT07284797Phase 1Recruiting
- Sponsor
- Xencor
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XmAb657 in idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and Sjögren's syndrome, sponsored by Xencor. Primary endpoint: Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) at 52 weeks. Started Feb 2026; status: recruiting.
02
Drugs
XmAb657
03
Conditions
idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07284797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284797.